...
首页> 外文期刊>Molecular cancer research: MCR >Suppression of the uPAR-uPA System Retards Angiogenesis, Invasion, and In Vivo Tumor Development in Pancreatic Cancer Cells.
【24h】

Suppression of the uPAR-uPA System Retards Angiogenesis, Invasion, and In Vivo Tumor Development in Pancreatic Cancer Cells.

机译:uPAR-uPA系统的抑制阻碍了胰腺癌细胞中的血管生成,侵袭和体内肿瘤的发展。

获取原文
获取原文并翻译 | 示例

摘要

Despite existing chemotherapy and surgical resection strategies, pancreatic cancer is one of the major causes of mortality in the United States with a 5-year mean survival rate of less than 5%. The activation of the urokinase-type plasminogen activator receptor-urokinase-type plasminogen activator (uPAR-uPA) system in the development of pancreatic ductal adenocarcinoma has been well established. In the present study, we used 2 pancreatic cancer cell lines, MIA PaCa-2 and PANC-1 to show the effects of uPAR and uPA downregulation. From the results, we observed that RNAi expressing plasmids efficiently downregulated mRNA and protein expression of uPAR and uPA. In vitro and in vivo angiogenic assays revealed a significant decrease in the angiogenic potential of MIA PaCa-2 and PANC-1 cells that were downregulated for both uPAR and uPA. From the angiogenesis antibody array analysis, we observed that the simultaneous downregulation of uPAR and uPA resulted in the downregulation of angiogenin and overexpression of RANTES. Further, FACS analysis showed that the simultaneous downregulation of uPAR and uPA caused the accumulation of cells in the sub-G(0/1) phase in both MIA PaCa-2 and PANC-1 cells. In addition, Western blot analysis revealed that downregulation of uPAR and uPA caused the activation of caspase 8 and CAD, which is indicative of apoptosis, and in vivo TUNEL assay confirmed these results. Finally, we observed the nuclear localization of uPA and that uPA interacts with the transcription factor Lhx-2. Taken together, the results of the present study show that the targeting of the uPAR-uPA system has therapeutic potential. Mol Cancer Res; 9(4); 377-89. (c)2011 AACR.
机译:尽管已有化学疗法和手术切除策略,胰腺癌仍是美国死亡的主要原因之一,其5年平均生存率低于5%。在胰腺导管腺癌的发展中,尿激酶型纤溶酶原激活物受体-尿激酶型纤溶酶原激活物(uPAR-uPA)系统的激活已被很好地建立。在本研究中,我们使用2种胰腺癌细胞系MIA PaCa-2和PANC-1来显示uPAR和uPA下调的作用。从结果,我们观察到表达RNAi的质粒有效下调了uPAR和uPA的mRNA和蛋白质表达。体外和体内血管生成分析显示,针对uPAR和uPA均被下调的MIA PaCa-2和PANC-1细胞的血管生成潜力显着降低。从血管生成抗体阵列分析,我们观察到uPAR和uPA的同时下调导致血管生成素的下调和RANTES的过表达。此外,FACS分析表明,uPAR和uPA的同时下调导致MIA PaCa-2和PANC-1细胞中sub-G(0/1)阶段的细胞蓄积。此外,蛋白质印迹分析表明,uPAR和uPA的下调引起caspase 8和CAD的激活,这表明细胞凋亡,体内TUNEL分析证实了这些结果。最后,我们观察了uPA的核定位,并且uPA与转录因子Lhx-2相互作用。综上所述,本研究的结果表明,靶向uPAR-uPA系统具有治疗潜力。分子癌症研究; 9(4); 377-89。 (c)2011年美国机修协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号